These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 12216376)

  • 21. Psychiatric Research Interview for Substance and Mental Disorders (PRISM): reliability for substance abusers.
    Hasin DS; Trautman KD; Miele GM; Samet S; Smith M; Endicott J
    Am J Psychiatry; 1996 Sep; 153(9):1195-201. PubMed ID: 8780425
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Views of Australian mental health stakeholders on clients' problematic drug and alcohol use.
    Cleary M; Hunt GE; Matheson S; Walter G
    Drug Alcohol Rev; 2009 Mar; 28(2):122-8. PubMed ID: 19320696
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Urban and rural utilization of evidence-based practices for substance use and mental health disorders.
    Dotson JA; Roll JM; Packer RR; Lewis JM; McPherson S; Howell D
    J Rural Health; 2014; 30(3):292-9. PubMed ID: 24702675
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A dual diagnosis typology to improve diagnosis and treatment of dual disorder patients.
    Zimberg S
    J Psychoactive Drugs; 1999; 31(1):47-51. PubMed ID: 10332638
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of co-occurring substance use on 6 month outcomes for young people seeking mental health treatment.
    Baker KD; Lubman DI; Cosgrave EM; Killackey EJ; Yuen HP; Hides L; Baksheev GN; Buckby JA; Yung AR
    Aust N Z J Psychiatry; 2007 Nov; 41(11):896-902. PubMed ID: 17924242
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Addiction psychiatry in specialized care--towards more precise differential diagnosis].
    Aalto M; Vorma H
    Duodecim; 2013; 129(19):2079-84. PubMed ID: 24218737
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mental health provider perspectives on co-occurring substance use among severely mentally ill clients.
    Mericle AA; Alvidrez J; Havassy BE
    J Psychoactive Drugs; 2007 Jun; 39(2):173-81. PubMed ID: 17703712
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adolescent substance abuse and psychiatric comorbidities.
    Deas D
    J Clin Psychiatry; 2006; 67 Suppl 7():18-23. PubMed ID: 16961420
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Dual diagnosis in psychoactive substance abusing or dependent persons].
    Błachut M; Badura-Brzoza K; Jarzab M; Gorczyca P; Hese RT
    Psychiatr Pol; 2013; 47(2):335-52. PubMed ID: 23888766
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dual diagnosis screening interview to identify psychiatric comorbidity in substance users: development and validation of a brief instrument.
    Mestre-Pintó JI; Domingo-Salvany A; Martín-Santos R; Torrens M;
    Eur Addict Res; 2014; 20(1):41-8. PubMed ID: 23921461
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Integrated versus parallel treatment of co-occurring psychiatric and substance use disorders.
    Mangrum LF; Spence RT; Lopez M
    J Subst Abuse Treat; 2006 Jan; 30(1):79-84. PubMed ID: 16377455
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Toward cost-effective care for persons with dual diagnoses.
    Jerrell JM
    J Ment Health Adm; 1996; 23(3):329-37. PubMed ID: 10172689
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence and profile of people with co-occurring mental and substance use disorders within a comprehensive mental health system.
    Rush B; Koegl CJ
    Can J Psychiatry; 2008 Dec; 53(12):810-21. PubMed ID: 19087479
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparisons of patients with comorbid psychiatric and substance use disorders: implications for treatment and service delivery.
    Havassy BE; Alvidrez J; Owen KK
    Am J Psychiatry; 2004 Jan; 161(1):139-45. PubMed ID: 14702262
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diagnosis of comorbid psychiatric disorders in substance users assessed with the Psychiatric Research Interview for Substance and Mental Disorders for DSM-IV.
    Hasin D; Samet S; Nunes E; Meydan J; Matseoane K; Waxman R
    Am J Psychiatry; 2006 Apr; 163(4):689-96. PubMed ID: 16585445
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Background and overview of mental health and substance abuse treatment systems: meeting the needs of women who are pregnant or parenting.
    Grella CE
    J Psychoactive Drugs; 1996; 28(4):319-43. PubMed ID: 9017555
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized clinical trial of a new behavioral treatment for drug abuse in people with severe and persistent mental illness.
    Bellack AS; Bennett ME; Gearon JS; Brown CH; Yang Y
    Arch Gen Psychiatry; 2006 Apr; 63(4):426-32. PubMed ID: 16585472
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Psychiatric comorbidity measures as predictors of retention in drug abuse treatment programs.
    Broome KM; Flynn PM; Simpson DD
    Health Serv Res; 1999 Aug; 34(3):791-806. PubMed ID: 10445903
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A dual diagnosis demonstration project: treatment outcomes and cost analysis.
    Judd PH; Thomas N; Schwartz T; Outcalt A; Hough R
    J Psychoactive Drugs; 2003 May; 35 Suppl 1():181-92. PubMed ID: 12825761
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Substance abuse relapse in a ten-year prospective follow-up of clients with mental and substance use disorders.
    Xie H; McHugo GJ; Fox MB; Drake RE
    Psychiatr Serv; 2005 Oct; 56(10):1282-7. PubMed ID: 16215196
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.